1998
NAIR ET AL.
ANTIMICROB. AGENTS CHEMOTHER.
cytidine. J. Virol. 66:7128–7135.
was toxic to granulocyte-macrophage (CFU-GM) progenitor
cells and erythroid (BFU-E) progenitor cells.
17. Ho, H.-T., and M. J. M. Hitchcock. 1989. Cellular pharmacology of 2Ј,3Ј-
dideoxy-2Ј,3Ј-didehydrothymidine, a nucleoside analog active against human
immunodeficiency virus. Antimicrob. Agents Chemother. 33:844–849.
18. Huryn, D. M., B. C. Sluboski, S. Y. Tam, M. Weigele, I. Sim, B. D. Anderson,
H. Mitsuya, and S. Broder. 1992. Synthesis and anti-HIV activity of iso-
nucleosides. J. Med. Chem. 35:2347–2354.
ACKNOWLEDGMENTS
The work performed at the University of Iowa by V. Nair and
coworkers was supported by the National Institutes of Health (NIAID)
through grant AI32851. HeLa-CD4-LTR--gal was obtained through
the AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH, from Michael Emerman.
IsoddATP was prepared by Todd B. Sells. We thank E. H. Dark, B.
Gallagher, L. Johnson, D. Selleseth, and S. Shaver for technical assis-
tance and M. Almond and T. S. Jahnke for help during the preparation
of the manuscript.
19. Jansen, R. W., L. C. Johnson, and D. R. Averett. 1993. High-capacity in vitro
assessment of anti-hepatitis B virus compound selectivity by a virion-specific
polymerase chain reaction assay. Antimicrob. Agents Chemother. 37:441–
447.
20. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent
and pseudotyped human immunodeficiency virus with a sensitive cell line on
the basis of activation of an integrated -galactosidase gene. J. Virol. 66:
2232–2239.
21. Larder, B. A. 1992. 3Ј-Azido-3Ј-deoxythymidine resistance supressed by a
mutation conferring human immunodeficiency virus type 1 resistance to
nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Che-
mother. 36:2664–2669.
22. Larder, B. A., B. Chesebro, and D. D. Richman. 1990. Susceptibilities of
zidovudine-susceptible and -resistant human immunodeficiency virus isolates
to antiviral agents determined by using a quantitative plaque reduction assay.
Antimicrob. Agents Chemother. 34:436–441.
23. Larder, B. A., K. E. Coates, and S. D. Kemp. 1993. Zidovudine-resistant
human immunodeficiency virus selected by passage in cell culture. J. Virol.
65:5232–5236.
24. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced
sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science
243:1731–1734.
25. Martin, J. L., C. E. Brown, N. Matthews-Davis, and J. E. Reardon. 1994.
Effects of antiviral nucleoside analogs on human DNA polymerases and
mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38:2743–
2749.
26. Mitsuya, H., and S. Broder. 1986. Inhibition of the in vitro infectivity and
cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-
associated virus (HTLV-III/LAV) by 2Ј,3Ј-dideoxynucleosides. Proc. Natl.
Acad. Sci. USA 83:1911–1915.
27. Mitsuya, H., R. F. Jarrett, M. Matsukura, F. D. M. Veronese, A. L. DeVico,
M. G. Sarngadharan, D. G. Johns, M. S. Reitz, and S. Broder. 1987. Long-
term inhibition of human T-lymphotropic virus type III/lymphadenopathy-
associated virus (human immunodeficiency virus) DNA synthesis and RNA
expression in T cells protected by 2Ј,3Ј-dideoxynucleosides in vitro. Proc.
Natl. Acad. Sci. USA 84:2033–2037.
28. Mitsuya, H., K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. N. Lehrman,
R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 1985. 3Ј-Azido-3Ј-
deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity
and cytopathic effect of human T-lymphotropic virus type III/lymphadenop-
athy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82:7096–7100.
29. Nair, V. 1993. Approaches to novel isomeric nucleosides as antiviral agents,
p. 127–140. In C. K. Chu and D. C. Baker (ed.), Nucleosides and nucleotides
as antitumor and antiviral agents. Plenum Press, New York.
30. Nair, V., and Z. M. Nuesca. 1992. Isodideoxynucleosides: a conceptually new
class of nucleoside antiviral agents. J. Am. Chem. Soc. 114:7951–7953.
31. Nair, V., and Z. M. Nuesca. 1994. Synthesis of novel 3Ј-isomeric dideoxy-
nucleosides. Tetrahedron Lett. 35:2485–2488.
REFERENCES
1. Ahluwalia, G., D. A. Cooney, N. R. Hartman, H. Mitsuya, R. Yarchoan, A.
Fridland, S. Broder, and D. G. Johns. 1993. Anomalous accumulation and
decay of 2Ј,3Ј-dideoxyadenosine 5Ј-triphosphate in human T-cell cultures
exposed to the anti-HIV drug 2Ј,3Ј-dideoxyinosine. Drug Metab. Dispos.
21:369–376.
2. Ahluwalia, G., D. A. Cooney, H. Mitsuya, A. Fridland, K. P. Flora, Z. Hao,
M. Dalal, S. Broder, and D. G. Johns. 1987. Initial studies on the cellular
pharmacology of 2Ј,3Ј-dideoxyinosine, an inhibitor of HIV infectivity. Bio-
chem. Pharmacol. 36:3797–3800.
3. Averett, D. R. 1989. Anti-HIV compound assessment by two novel high-
capacity assays. J. Virol. Methods 23:263–276.
4. Bolon, P. J., T. B. Sells, Z. M. Nuesca, D. F. Purdy, and V. Nair. 1994. Novel
isomeric dideoxynucleosides as potential antiviral agents. Tetrahedron 50:
7747–7764.
5. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schurman, P. Rouse, M. A.
Wainberg, and J. M. Cameron. 1993. High-level resistance to (Ϫ) enantio-
meric 2Ј-deoxy-3Ј-thiacytidine in vitro is due to one amino acid substitution
in the catalytic site of human immunodeficiency virus type 1 reverse tran-
scriptase. Antimicrob. Agents Chemother. 37:2231–2234.
6. Chu, C. K., R. F. Schinazi, B. H. Arnold, D. L. Cannon, B. Doboszewski, V. B.
Bhadti, and Z. Gu. 1988. Comparative activity of 2Ј,3Ј-saturated and unsat-
urated pyrimidine and purine nucleoside analogs on mitochondrial DNA
and its implication for delayed toxicity. Mol. Pharmacol. 39:625–628.
7. Coates, J. A. V., N. Cammack, H. J. Jenkinson, I. M. Mutton, B. A. Pearson,
R. Storer, J. M. Cameron, and C. R. Penn. 1992. The separated enantiomers
of 2Ј-deoxy-3Ј-thiacytidine (BCH-189) both inhibit human immunodefi-
ciency virus replication in vitro. Antimicrob. Agents Chemother. 36:202–205.
8. Condreay, L. D., R. W. Jansen, L. C. Johnson, T. Powdrill, D. Sellseth, S. M.
Daluge, G. Painter, P. A. Furman, M. N. Ellis, and D. R. Averett. 1994. A
murine model for anti-hepatitis B virus compound assessment in vivo. An-
timicrob. Agents Chemother. 38:616–619.
9. Daluge, S. M., D. J. M. Purifoy, P. M. Savina, M. H. St. Clair, N. R. Parry,
I. K. Dev, P. Novak, K. M. Ayers, J. E. Reardon, G. B. Roberts, J. A. Fyfe,
M. R. Blum, D. R. Averett, R. E. Dornsife, B. A. Domin, R. Ferone, D. A.
Lewis, and T. A. Krenitsky. 1994. 5-Chloro-2Ј,3Ј-dideoxy-3Ј-fluorouridine
(BW935U83): a selective anti-human immunodeficiency virus agent with
improved pharmacokinetic and toxicological properties. Antimicrob. Agents
Chemother. 38:1590–1603.
10. De Clercq, E. 1994. Antiviral activity spectrum and target of action of dif-
ferent classes of nucleoside analogues. Nucleosides Nucleotides 13:1271–
1295.
31a.National Institutes of Health. 1985. Guide for care and use of laboratory
animals. DHHS publication no. (NIH) 85-23. U.S. Department of Health
and Human Services, Washington, D.C.
32. Paff, M. T., D. R. Averett, K. L. Prus, W. H. Miller, and D. J. Nelson. 1993.
Intracellular metabolism of (Ϫ)- and (ϩ)-cis-5-fluoro-1-[2-(hydroxymethyl-
1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells.
Antimicrob. Agents Chemother. 38:1230–1238.
11. De Clercq, E. 1994. HIV resistance to reverse transcriptase inhibitors. Bio-
chem. Pharmacol. 47:155–169.
12. Dornsife, R. E., M. H. St. Clair, A. T. Huang, T. J. Panella, G. W. Koszalka,
C. L. Burns, and D. R. Averett. 1991. Anti-human immunodeficiency virus
synergism by zidovudine (3Ј-azidothymidine) and didanosine (dideoxy-
inosine) contrasts with their additive inhibition of normal human marrow
progenitor cells. Antimicrob. Agents Chemother. 35:322–328.
13. Fischer, A. G., E. Collati, L. Ratner, R. C. Gallo, and F. Wong-Staal. 1985.
A molecular clone of HTLV-III with biological activity. Nature (London)
316:262–265.
14. Furman, P. A., J. A. Fyfe, M. H. St Clair, K. Weinhold, J. L. Rideout, G. A.
Freeman, S. N. Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, and D. W.
Barry. 1986. Phosphorylation of 3Ј-azido-3Ј-deoxythymidine and selective
interaction of the 5Ј-triphosphate with human immunodeficiency virus re-
verse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333–8337.
33. Prus, K. L., D. R. Averett, and T. P. Zimmerman. 1990. Transport and
D-arabinofuranosylguanine in a human T-lymphoblastoid
metabolism of 9--
cell line: nitrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res.
50:1817–1821.
34. Richman, D. D. 1991. Selection of AZT-resistant variants by therapy. J. NIH
Res. 3:83–87.
35. Schinazi, R. F., R. J. Lloyd, M.-H. Nguyen, D. L. Cannon, A. McMillan, N.
Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993.
Characterization of human immunodeficiency viruses resistant to oxathio-
lane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875–881.
36. Schinazi, R. F., J. R. Mead, and P. M. Feorino. 1992. Insights into HIV
chemotherapy. AIDS Res. Hum. Retroviruses 8:963–990.
37. Sells, M. A., M.-L. Chen, and G. Acs. 1987. Production of hepatitis B virus
particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc.
Natl. Acad. Sci. USA 84:1005–1009.
38. Sells, T. B., and V. Nair. 1994. Synthetic approaches to novel cis and trans
dideoxynucleosides of the apiose family. Tetrahedron 50:117–138.
39. Shirasaka, T., K. Murakami, H. Ford Jr., J. A. Kelley, H. Yoshioka, E.
Kojima, S. Aoki, S. Broder, and H. Mitsuya. 1990. Lipophilic halogenated
congeners of 2Ј,3Ј-dideoxypurine nucleosides active against human immu-
15. Gao, Q., Z. X. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher,
and M. A. Wainberg. 1993. The same mutation that encodes low-level human
immunodeficiency virus type 1 resistance to 2Ј,3Ј-dideoxyinosine and 2Ј,3Ј-
dideoxycytidine confers high-level resistance to the (Ϫ) enantiomer of 2Ј,3Ј-
dideoxy-3Ј-thiacytidine. Antimicrob. Agents Chemother. 37:1390–1392.
16. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992. Novel
mutation in the human immunodeficiency virus type 1 reverse transcriptase
gene that encodes cross-resistance to 2Ј,3Ј-dideoxyinosine and 2Ј,3Ј-dideoxy-